July 14, 2008 – Quintiles Transnational Corp. has been named to ~LT~i~GT~Computerworld~LT~/i~GT~ magazine’s 2008 list of the "100 Best Places to Work in IT." Each year, the magazine publishes the results of its Best Places to Work in IT survey recognizing the top 100 companies in the United States that offer their IT staff a challenging and satisfying work environment.

June 6, 2008 – Quintiles Transnational Corp. today announced the appointment of Christopher H. Cabell, M.D., MHS, FACC, as Chief Medical and Scientific Officer.  Cabell succeeds Oren Cohen, M.D., who was recently appointed Senior Vice President, Clinical Research Strategies.

April 22, 2008 – Quintiles Transnational Corp. today announced the appointment of three new practice leaders and a business development head as part of its expanding Quintiles Consulting business, which provides pharmaceutical, biotech and medical device companies with strategic guidance to maximize potential and minimize risk from early discovery through commercialization.

April 16, 2008 – Quintiles Transnational Corp. today announced the appointment of Oren Cohen, M.D. as Senior Vice President, Clinical Research Strategies.

February 13, 2008 – Quintiles Transnational Corp. today announced that its central laboratory in India has been certified by the College of American Pathologists (CAP).

RESEARCH TRIANGLE PARK, N.C. – January 24, 2008 – Quintiles Transnational Corp. today announced the completion of its previously announced new investor partnership to support the company’s continued growth under the leadership of founder and current Chairman and CEO Dennis Gillings, CBE, and the management team.

January 9, 2008 – Quintiles Transnational Corp. today announced the appointment of Kelly McKee, M.D., as Executive Director of Operations for the company’s Public Health and Government Services unit.  McKee brings tremendous experience and expertise in infectious diseases and vaccine product development.

January 8, 2008 – Quintiles Transnational Corp. today announced the appointment of Dipti Amin, M.D., as Senior Vice President of Strategic Research and Safety Services (SRS) and Medical and Regulatory Services, effective immediately.

December 21, 2007 – Quintiles Transnational Corp. today announced the formation of a new investor partnership to support the company’s continued growth under the leadership of current Chairman and CEO Dennis Gillings, CBE, and the management team. Gillings and global private investment firms Bain Capital and TPG Capital are the lead investors in the partnership, with 3i also becoming a significant investor. Temasek Holdings remains an investor in Quintiles.

December 11, 2007 - Quintiles Transnational Corp. today announced the appointment of John Goodacre as Executive Vice President and General Counsel.

Nov. 12, 2007 – ForceLogix and Innovex have received the Ventana Research 2007 Operational Performance Leadership Award for Sales, honoring the companies’ combined excellence in orchestrating people, process, information and technology for optimal sales business impact.

October 26, 2007 – Quintiles Transnational Corp. today announced that Christopher H. Cabell, M.D., MHS, FACC, an expert cardiologist and clinical investigator, has joined the Medical & Scientific Services group in Global Clinical Development Services (CDS).  In addition to his CDS work, he provides U.S.-based cardiology expertise for Quintiles ECG Services.

August 15, 2007 – Quintiles Transnational Corp. today announced the appointment of Michael Troullis as its Chief Financial Officer, effective immediately.  Troullis had been acting CFO since former CFO John Ratliff was appointed Quintiles’ Chief Operating Officer last year.

June 21, 2007 – Quintiles Transnational Corp. today announced that clinical investigators rate their relationships with Quintiles the best in the industry, according to a recent survey.

May 21, 2007 – Quintiles Transnational Corp. and Thermo Fisher Scientific Inc. (NYSE: TMO) have announced the creation of a joint venture, called Cenduit™, that provides seamless, integrated Interactive Response Technology (IRT) services for pharmaceutical and biotechnology product development.